Competitive advantage of hematopoietic stem cells
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Ex vivo expansion of human hematopoietic stem cells (HSCs) is of central importance for modern gene and cell therapies, as it provides sufficient cell numbers for genetic modification and subsequent transplantation, as well as for the manufacture of complex immune-cell products. A persistent challenge, however, is the progressive loss of stemness and clonogenic capacity during extended culture, which limits the applicability of existing protocols. This work aimed to establish a defined, temporally controllable stimulation system capable of supporting a long-term, controlled expansion of HSCs without impairing their functional properties. To achieve this, a chemically inducible c-KIT receptor was generated by fusing its intracellular domain to the F36V mutant of FKBP12 (phenylalanine-to-valine substitution at position 36). This mutation confers selective binding to the synthetic dimerizer Rimiducid, allowing controlled activation of c-KIT signaling in primary human CD34⁺ cells. This platform enables precise and reversible activation of the c-KIT signaling pathway, clearly separating cell-intrinsic signaling events from external growth-factor stimulation. Following a single application of the chemical inducer of the reporter system (25 nM Rimiducid (RC)), an early and significant increase was observed during the first two culture days in both the total CD34⁺ population and the immunophenotypically defined long-term HSCs (CD34⁺/CD38⁻/CD133⁺). This effect then gradually declined and was largely resolved by day 8. Under these conditions, clonogenic capacity remained intact, indicating a time-limited expansion with maintained clonogenic potential. To assess the impact of dose and stimulation interval, repeated stimulations were performed. Low-dose Rimiducid applications (25 nM every 48 h) produced a sustained increase in cell numbers of the transduced cells, whereas repeated applications of high Rimiducid concentrations (100 nM) led, depending on the experimental setting, to a marked reduction in colony formation and cell viability, thereby defining a narrow therapeutic window for c-KIT activation. Accompanying short-term phospho-kinase analyses revealed enhanced JNK/CREB and moderate ERK signaling together with a reduction in AKT/c-Jun phosphorylation, providing initial insights into the signaling cascades involved. In summary, this work demonstrates that dose and stimulation interval are criticalparameters for achieving a long-term, controlled expansion of transduced HSCs. The described system offers a scalable and precisely regulatable strategy with significant practical relevance for the development and manufacturing of future gene- and cell-therapy products, including CAR-T and other immune-cell-based applications.
Fields of Study & Subjects
Hematopoietic Stem Cell Transplantation
Mesenchymal stem cell research
Pluripotent Stem Cells Research
Publication details
- Publication date
- 27 March 2026
- Language
- EN
- Document type
- Thesis